AEterna Zentaris Inc (NASDAQ:AEZS)

0.2843
Delayed Data
As of 3:59pm ET
 -0.0107 / -3.63%
Today’s Change
0.26
Today|||52-Week Range
1.54
-52.62%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$28.0M

Company Description

AEterna Zentaris, Inc. engages in the development of novel treatments in oncology and endocrinology, which currently investigating treatments for various unmet medical needs. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Quebec, Canada.

Contact Information

Æterna Zentaris, Inc.
1405, boulevard du Parc-Technologiqu
Québec Quebec G1P 4P5
P:(418) 652-8525
Investor Relations:
14186528525406

Employees

Shareholders

Other institutional18.44%
Mutual fund holders0.01%
Individual stakeholders--

Top Executives

David A. DoddChairman, President & Chief Executive Officer
Dennis TurpinChief Financial Officer & Senior Vice President
Richard SachseSenior VP, Chief Scientific & Medical Officer
Philip A. TheodoreSecretary, Chief Administrative Officer & SVP
Paul BurroughsCommunications Director & Head-Media Relations

To view my watchlist

Not a member yet?

Sign up now for a free account